← back to the index
DV-013 orthopedics 2012

The Stryker Rejuvenate and ABG II — Hip Stems That Corroded for $1.4 Billion

corrosionmetal-toxicity-metallosisrevision-surgeryorthopedic-surgery2010s
Patients implanted
~20,000 worldwide (Howmedica Osteonics)
Failure or harm
Fretting/galvanic corrosion at the neck-stem taper → metallosis, ALTR, revision; ~3,700 suits by Jul 2014
In use
~4 yrs (2008/2009 launch – Jul 2012 recall)
Status
Recalled (Class I)

Summary

When Howmedica Osteonics, the orthopedic subsidiary of Stryker Corporation, posted an "Urgent Field Safety Notice" on July 3, 2012 withdrawing its Rejuvenate and ABG II modular-neck hip stems, the gap between the design's selling point and its failure was already inscribed in the chemistry: the very feature marketed as an advance — a separable, surgeon-selectable metal neck joining the femoral stem at a second taper — was the site where the device destroyed itself. The stem was titanium alloy; the neck was cobalt-chromium. The two dissimilar metals, locked at a Morse taper and loaded with every step a patient took, fretted and corroded galvanically, shedding cobalt and chromium ions and metallic debris into the hip. Roughly 20,000 of the stems had been implanted before the recall.

The harm was not mechanical loosening of the kind orthopedics had long understood. It was a slow metallic poisoning of the joint. Released cobalt and chromium provoked adverse local tissue reactions — pseudotumors, fluid collections, and necrosis of muscle and bone — while systemic ion levels rose in the bloodstream, a condition clinicians call metallosis. Patients presented with pain, swelling, and instability; many were asymptomatic until imaging or blood testing revealed elevated metal levels and tissue destruction already underway. The remedy was rarely conservative. Revision surgery — extraction of a corroded, often well-fixed stem and replacement of the damaged joint — became the common endpoint, with its own attendant risks of fracture, infection, and permanent disability.

The Rejuvenate had reached the market not through clinical trials but through the FDA's 510(k) pathway, cleared in June 2008 as "substantially equivalent" to predicate devices already on sale; the ABG II followed in November 2009. No premarket study had been required to prove that the modular junction was durable in living bodies. By July 2014 roughly 3,700 patients had sued. The litigation consolidated into a multidistrict proceeding in federal court in Minnesota and a coordinated docket before Judge Brian R. Martinotti in Bergen County, New Jersey, and on November 3, 2014 Stryker announced a settlement paying a base award of $300,000 per failed device removed, with enhancements for complications — a program that grew, through later expansions covering revisions into December 2016, to a payout exceeding $1.4 billion. The modular hip that promised the surgeon a custom fit became the textbook case of taper-junction corrosion and the limits of clearing an implant by analogy rather than evidence.

Timeline

Jun 2008
Rejuvenate cleared via 510(k)
The FDA clears the Rejuvenate Modular-Neck stem as substantially equivalent to predicate devices; no premarket clinical trial of the junction's in-body durability is required.
Nov 2009
ABG II cleared
Howmedica Osteonics obtains 510(k) clearance for the companion ABG II modular-neck stem, extending the same dual-metal taper concept.
2009–2012
Mass implantation
Surgeons implant roughly 20,000 of the two stems worldwide, marketing the modular neck as letting them tune leg length, offset, and version intraoperatively.
Jan 2012
Adverse-event reports accumulate
The FDA logs a rising stream of adverse-event reports tied to the modular-neck stems — pain, swelling, and metal-debris reactions.
Apr 2012
Stryker tightens guidance
Stryker issues clarified instructions and warns clinicians of the potential for fretting and corrosion at the neck-stem junction.
Jul 3, 2012
Voluntary worldwide recall
Howmedica Osteonics withdraws both the Rejuvenate and ABG II modular-neck stems, citing fretting and/or corrosion at the modular junction that may cause adverse local tissue reactions.
2012
FDA classifies as Class I
The action is designated a Class I recall — the agency's most serious category, reserved for defects that may cause serious injury or death.
2012–2013
Surveillance protocol
Stryker advises implanted patients, including the asymptomatic, to undergo blood testing for cobalt and chromium and cross-sectional imaging for pseudotumors.
Jun 2013
Litigation consolidates
Cases are centralized: a federal MDL in the District of Minnesota and a coordinated New Jersey docket before Judge Brian R. Martinotti in Bergen County.
Nov 3, 2014
$300,000-per-device settlement
Stryker announces a settlement paying a gross base award of $300,000 per failed implant removed, plus enhancements; reported total value exceeds $1 billion.
2016–2018
Settlement expanded
Later programs extend eligibility to patients revised through December 19, 2016, lifting Stryker's disclosed payout above $1.4 billion.

The Selling Point Was the Defect

The Rejuvenate's marketing logic was seductive and, on its face, surgical common sense. Conventional femoral stems fix the neck angle, offset, and version at the factory; the modular design split the neck from the stem so the surgeon could mix and match components on the operating table to reconstruct a given patient's anatomy. That flexibility was the pitch. It also created a second metal-on-metal interface inside the implant — a Morse taper where a cobalt-chromium neck seated into a titanium stem. Dissimilar metals in a salt-water electrolyte are a galvanic cell. Under the cyclic micromotion of gait, the junction underwent fretting corrosion: protective oxide films were mechanically abraded, exposed metal re-corroded, and the cycle ground cobalt and chromium loose. The engineering hazard of joining two different metals at a loaded taper was not novel; it was the predictable downside of the very feature being sold as innovation.

Metallosis and the Asymptomatic Trap

The clinical signature distinguished this failure from ordinary hip wear. Instead of loosening from polyethylene debris, patients accumulated metal. Cobalt and chromium ions and particulate corrosion products triggered adverse local tissue reactions — inflammatory pseudotumors, sterile fluid collections, and necrosis that could dissolve the abductor muscles and erode bone around an implant that was otherwise solidly fixed. The most troubling feature was its silence: Stryker had to warn that patients with no pain at all were turning up with toxic metal-ion levels and tissue damage on imaging, which is why the company urged blood testing and scans even of those who felt fine. A well-fixed, corroding stem is harder to remove than a loose one; revision often meant cutting through scarred, metal-stained tissue, sometimes splitting the femur to extract a stem the body had grown around — major surgery to undo a device that had been implanted to last decades.

Cleared by Analogy, Settled by the Thousands

The reckoning exposed the pathway as much as the product. Neither stem had passed a premarket clinical trial; both entered the market through the FDA's 510(k) process, which clears a device on a showing that it is "substantially equivalent" to something already sold. The modular junction's behavior in living, weight-bearing bodies had never been required to be proven. When failures mounted, the remedy came through tort, not regulation: roughly 3,700 suits by July 2014, consolidated into a Minnesota federal MDL and Judge Martinotti's New Jersey docket. Stryker's November 3, 2014 settlement set a base of $300,000 per removed device — among the largest individual base awards in mass-tort hip litigation — and the program, expanded to cover later revisions, ultimately carried Stryker's disclosed payout past $1.4 billion. The recall withdrew the stems from shelves; it did nothing for the metal already corroding in tens of thousands of hips, which only surgery could address.

Contributing Factors

01
A second metal junction designed into a load path
Splitting the neck from the stem to give surgeons modular fit introduced an additional Morse taper bearing the full cyclic load of gait. Every loaded interface between dissimilar metals is a corrosion site; the design's marketed advantage was structurally identical to its failure mechanism.
02
Dissimilar-metal galvanic coupling
Pairing a cobalt-chromium neck with a titanium-alloy stem in the body's saline environment created a galvanic cell. Fretting abraded the passivating oxide layer and exposed fresh metal to corrode, a self-reinforcing electrochemical process that no amount of post-market patient education could halt.
03
Clearance by substantial equivalence, not evidence
Both stems reached patients through the 510(k) pathway, cleared as analogues of predicate devices without a trial demonstrating the junction's durability in vivo. The regulatory shortcut let a novel corrosion geometry enter ~20,000 bodies before its in-use behavior was ever measured.
04
A failure mode that was often silent until severe
Because metallosis and adverse tissue reaction could advance without pain, harm was frequently discovered only after tissue and bone were already destroyed. The mismatch between symptom onset and damage onset delayed detection and converted a monitoring problem into an irreversible-injury problem.
05
Withdrawal that left the hazard implanted
Recalling the stems from distribution removed future sales but not the corroding devices already in patients, for whom the only true remedy was revision surgery. Treating market withdrawal as resolution, rather than retrieval of an in-body hazard, pushed the cost and risk onto the patients and the courts.

Aftermath

The Rejuvenate and ABG II withdrawal became a turning point in how orthopedics regards modular junctions. The episode hardened clinical consensus that any additional metal-on-metal taper is a corrosion liability to be justified, not assumed, and it folded into the broader collapse of confidence in metal-bearing hips that had already engulfed the DePuy ASR. Surveillance for cobalt and chromium ions and cross-sectional imaging for pseudotumors entered routine follow-up for modular and metal-on-metal patients. Financially, Stryker's disclosed settlement burden climbed past $1.4 billion as eligibility expanded to revisions through December 2016, on a base award of $300,000 per failed device — figures that made the case a benchmark in device mass-tort accounting. Regulators and reviewers cited it among the implants that exposed the 510(k) clearance pathway's central weakness: that a device can reach tens of thousands of bodies on a claim of resemblance to a predecessor, with no requirement to prove the part that fails. Today the Rejuvenate stem is shorthand for taper-junction corrosion and for the danger of mistaking modular convenience for clinical progress.

Lessons

  1. Treat every added junction in a load-bearing implant as a failure site to be justified by evidence, not a feature to be marketed — convenience at an interface is paid for in corrosion.
  2. Never couple dissimilar metals across a loaded taper in the body without proving the galvanic-fretting behavior in vivo first; chemistry does not defer to a sales advantage.
  3. Distrust "substantial equivalence" when the novelty is precisely the part that can fail — clearance by analogy certifies resemblance, not the durability of the new geometry.
  4. Build active surveillance for any failure mode that can advance without symptoms; when harm outruns pain, routine monitoring is the only thing standing between a defect and an irreversible injury.
  5. Separate recall from remedy: withdrawing a device from sale does nothing for the units already implanted, so plan and fund retrieval of the in-body hazard, not merely the end of distribution.

References